Latest Clinical News

Using the Internet Wisely for Cancer Information (07-11-2019)

From Beth Israel Deaconess Medical Center The Internet is simultaneously the best and the worst of tools. This is especially true when related to a cancer patient’s search for support and information. Whereas people used to have to find medical libraries... Continue Reading

New Surgical Technique Shows Potential in Restoring Erectile Function After Radical Prostatectomy (07-9-2019)

Cancer Connect News: According to a report from Australian doctors published in the Journal of European Urology minimally invasive end to end nerve grafting can restore erectile function among men who previously underwent radical prostatectomy for prostate... Continue Reading

FDA Approves New Treatment for Multiple Myeloma (07-5-2019)

The FDA has granted accelerated approval to selinexor (Xpovio; Karyopharm Therapeutics) tablets in combination with the corticosteroid dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who received ≥4 previous therapies... Continue Reading

NIH study finds long-term increased risk of cancer death following common treatment for hyperthyroidism (07-2-2019)

Findings from a study of patients who received radioactive iodine (RAI) treatment for hyperthyroidism show an association between the dose of treatment and long-term risk of death from solid cancers, including breast cancer. The study, led by researchers... Continue Reading

Darzalex Approved for Newly Diagnosed Stem Cell Transplant Ineligible Multiple Myeloma Patients (07-1-2019)

Darzalex (daratumumab) in combination with Revlimid (lenalidomide) and dexamethasone has been approved by the US Food and Drug Administration  for treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem... Continue Reading

FDA Approves Polatuzumab Vedotin-Piiq for Diffuse Large B-Cell Lymphoma (06-25-2019)

​The FDA granted accelerated approval to polatuzumab vedotin-piiq, a CD79b-directed antibody-drug conjugate indicated in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma... Continue Reading

FDA Approves Keytruda for Small Cell Lung Cancer (06-18-2019)

The  Food and Drug Administration granted accelerated approval to Keytruda (pembrolizumab) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of... Continue Reading

FDA Approves Keytruda for First-line Treatment of Head and Neck Squamous Cell Carcinoma (06-13-2019)

FDA approves Keytruda for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). Keytruda was approved for use in combination with platinum and fluorouracil (FU) for all patients and... Continue Reading

FDA Approves Chemoimmunotherapy Regimen for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (06-11-2019)

The U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy Treanda (bendamustine) and Rituxan (rituximab) product (a combination known as “BR”), to treat adult... Continue Reading

Three-drug Combination Helps Curb Growth of Deadly Skin Cancer (06-10-2019)

A UCLA-led research team has pinpointed a three-drug combination that could prove to be an effective new therapy for people with a specific type of advanced melanoma. The approach shows promise for extending the lives of people with a type of melanoma... Continue Reading

Immunotherapy comparable to chemo for some advanced stomach cancers (06-4-2019)

An immunotherapy drug could prove just as effective as chemotherapy in prolonging the lives of patients with advanced cancers of the stomach or food pipe. For some, the immune-boosting treatment offered improved survival compared to standard treatment. The... Continue Reading

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer (06-3-2019)

After 3 years, 80% of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with testosterone suppression were alive compared to 72% of men who received standard care. Chicago – Enzalutamide, an oral androgen receptor... Continue Reading

Next Page »